Home LiteratureArticle Details
PMID: 11406496 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Protection of ischemic hearts by high glucose is mediated, in part, by GLUT-4.

American journal of physiology. Heart and circulatory physiology ·Vol. 281 ·No. 1 ·2001-07-00 ·Pages H290-7

Ramasamy R, Hwang YC, Whang J, Bergmann SR

Abstract

Metabolic interventions that promote glucose use during ischemia have been shown to protect ischemic myocardium and improve functional recovery on reperfusion. We evaluated whether the cardioprotection afforded by high glucose during low-flow ischemia is associated with changes in the sarcolemmal content of glucose transporters, specifically GLUT-4. Isolated rat hearts were paced at 300 beats/min and perfused under normal glucose (5 mM) or high glucose (10 mM) conditions in buffer containing 0.4 mM albumin, 0.4 mM palmitate, and 70 mU/l insulin and subjected to 50 min of low-flow ischemia and 60 min of reperfusion. To determine the importance of insulin-sensitive glucose transporters in mediating cardioprotection, a separate group of hearts were perfused in the presence of cytochalasin B (10 microM), a preferential inhibitor of insulin-sensitive glucose transporters. Ischemic contracture during low-flow ischemia and creatine kinase release on reperfusion was decreased, and the percent recovery of left ventricular function with reperfusion was enhanced in hearts perfused with high glucose (P < 0.03). Hearts perfused with high glucose exhibited increased GLUT-4 protein expression in the sarcolemmal membrane compared with control hearts under baseline conditions, and these changes were additive with low-flow ischemia. In addition, high glucose did not affect the baseline distribution of sarcolemmal GLUT-1 and blunted any changes with low-flow ischemia. These salutary effects were abolished when glucose transporters are blocked with cytochalasin B. These data demonstrate that protection of ischemic myocardium by high glucose is associated with increased sarcolemmal content of the insulin-sensitive GLUT-4 and suggest a target for the protection of jeopardized myocardium.

MeSH Terms
Animals Creatine Kinase/metabolism Cytochalasin B/pharmacokinetics,pharmacology Dose-Response Relationship, Drug Glucose/pharmacology,physiology Glucose Transporter Type 1 Glucose Transporter Type 4 Heart/drug effects,physiopathology Hemodynamics/drug effects In Vitro Techniques Intracellular Membranes/metabolism Lactic Acid/metabolism Monosaccharide Transport Proteins/metabolism,physiology Muscle Proteins Myocardial Ischemia/physiopathology Myocardium/metabolism Protective Agents/pharmacology Rats Rats, Wistar Sarcolemma/metabolism
Chemicals
Glucose Transporter Type 1 Glucose Transporter Type 4 Monosaccharide Transport Proteins Muscle Proteins Protective Agents Slc2a1 protein, rat Slc2a4 protein, rat Lactic Acid Cytochalasin B Creatine Kinase Glucose
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ramasamy R
Division of Cardiology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA. rr260@columbia.edu
Hwang Y C
Whang J
Bergmann S R
Article Info
Journal
American journal of physiology. Heart and circulatory physiology
Abbr.
Am J Physiol Heart Circ Physiol
ISSN
0363-6135
Published
2001-07-00
Pages
H290-7
Language
English
Region
United States
NLM ID
100901228
Subset
IM
Grants
NHLBI NIH HHS · HL-58408 · United States
NHLBI NIH HHS · HL-61783 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com